Silver Book Fact

A calculated approximate benefit-to-cost ratio for antihypertensive therapy is 10:1 for men and 6:1 for women.

Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Every $1 spent on technological innovations in heart attack care has produced an estimated $7 gain.  
  • Increased Use of Medicines Reduces Risk of Death After Major Cardiovascular Events: Disease management program increased use of medicines  
  • Stroke prevention through optimal anticoagulation
    If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.  
  • Heart Failure Disease Management (DM) Program Reduces Hospitalizations and Overall Costs  
  • Anti-platelet therapy stroke risk reduction
    Anti-platelet therapy after a stroke or TIA reduces the risk of nonfatal ischemic strokes by 28% and fatal strokes by 16%.